Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
GFARB12019
1 other identifier
observational
3,000
5 countries
6
Brief Summary
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 4, 2020
CompletedFirst Posted
Study publicly available on registry
June 11, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
March 2, 2026
February 1, 2026
8.2 years
June 4, 2020
February 27, 2026
Conditions
Outcome Measures
Primary Outcomes (5)
Number of cases with retinoblastoma in each participating hospital.
Evaluation of the number of cases registered .
10 years
Number of cases with stage 2 disease
Evaluation of the number of cases registered with stage 2 disease.
10 years
Feasibility of these therapeutic recommendations in an African setting
Evaluate the application of these therapeutic recommendations
10 years
Evaluating the treatment given.
Comparison of treatment given and recommended treatment.
10 years
follow up
analysis of the number of children alive or dead after treatment
10 years
Interventions
We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
Eligibility Criteria
all children presenting at participating units who can be treated
You may qualify if:
- Unilateral intraocular Retinoblastoma (RB)
- Unilateral extraocular intraorbital (RB)
- Bilateral intraocular (RB)
- bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.
You may not qualify if:
- Externalized tumor mass
- massive extension to optic nerve up to optical channeltumor
- intracranial extension leptomeninges
- cerebral parenchyma
- extension to regional lymph nodes and/or remote metastases.
- cerebrospinal fluid involvement.
- Trilateral RB
- Incapacity to followed the whole treatement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Hopital Yalgado Ouedraogo
Ouagadougou, 03 BP 7022, Burkina Faso
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire
CUK (Cliniques Universitaires de Kinshasa)
Kinshasa, Kinshasa City, BP 12 KIN XI, Democratic Republic of the Congo
Cliniques Universitaires de Lubumbashi (CUL)
Lubumbashi, BP 1825, Democratic Republic of the Congo
HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
Antananarivo, Ampefiloha, BP 4150, Madagascar
CHU Gabriel Touré (HGT)
Bamako, Mali
Hôpital Aristide Le Dantec,
Dakar, BP 3001, Senegal
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
FOUSSEYNI Mr TRAORE, Dr;
AMCC AND GFAOP
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2020
First Posted
June 11, 2020
Study Start
November 1, 2020
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2030
Last Updated
March 2, 2026
Record last verified: 2026-02